What Is Wrong with Orphan Drug Policies? Suggestions for Ways Forward
- 1 December 2012
- journal article
- Published by Elsevier in Value in Health
- Vol. 15 (8) , 1182-1184
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- What Is Wrong with Orphan Drug Policies?Value in Health, 2012
- Rare cancers are not so rare: The rare cancer burden in EuropeEuropean Journal of Cancer, 2011
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- A comparative study of European rare disease and orphan drug marketsHealth Policy, 2010
- Expansion of cancer care and control in countries of low and middle income: a call to actionThe Lancet, 2010
- Is it time to revisit orphan drug policies?BMJ, 2010
- Does orphan drug legislation really answer the needs of patients?The Lancet, 2008
- The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)Annals of Oncology, 2007
- Assessing the economic challenges posed by orphan drugsInternational Journal of Technology Assessment in Health Care, 2007
- Orphan drugs and the NHS: should we value rarity?BMJ, 2005